-
Gene expression profiling in elderly patients with familial hypercholesterolemia with and without coronary heart disease Atherosclerosis (IF 5.3) Pub Date : 2024-03-11 Torunn Melnes, Martin P. Bogsrud, Jacob J. Christensen, Amanda Rundblad, Ingunn Narverud, Kjetil Retterstøl, Pål Aukrust, Bente Halvorsen, Stine M. Ulven, Kirsten B. Holven
Elderly familial hypercholesterolemia (FH) patients are at high risk of coronary heart disease (CHD) due to high cholesterol burden and late onset of effective cholesterol-lowering therapies. A subset of these individuals remains free from any CHD event, indicating the potential presence of protective factors. Identifying possible cardioprotective gene expression profiles could contribute to our understanding
-
Neurotensin: Linking metabolism and cardiovascular disease Atherosclerosis (IF 5.3) Pub Date : 2024-03-08 Ilaria Barchetta, Maria Gisella Cavallo
-
Multifaceted roles of Meg3 in cellular senescence and atherosclerosis Atherosclerosis (IF 5.3) Pub Date : 2024-03-08 Xiao Cheng, Mohamed Sham Shihabudeen Haider Ali, Vijaya Bhaskar Baki, Matthew Moran, Huabo Su, Xinghui Sun
Long noncoding RNAs are involved in the pathogenesis of atherosclerosis. As long noncoding RNAs maternally expressed gene 3 (Meg3) prevents cellular senescence of hepatic vascular endothelium and obesity-induced insulin resistance, we decided to examine its role in cellular senescence and atherosclerosis. By analyzing our data and human and mouse data from the Gene Expression Omnibus database, we found
-
Circulating miR-6821-5p levels and coronary calcification in asymptomatic familial hypercholesterolemia patients Atherosclerosis (IF 5.3) Pub Date : 2024-03-08 Rafael Escate, Teresa Padró, Leopoldo Pérez de Isla, Francisco Fuentes, Rodrigo Alonso, Pedro Mata, Lina Badimon
Premature atherosclerotic cardiovascular disease (CVD) is a clinic characteristic of familial hypercholesterolemia (FH). Coronary calcium score (CCS) is a highly used imaging modality to evidence atherosclerotic plaque burden. microRNAs (miRNAs) are non-coding RNAs that epigenetically regulate gene expression. Here, we investigated whether CCS associates with a specific miRNA-signature in FH-patients
-
Coronary artery calcium: The canary in the coal mine Atherosclerosis (IF 5.3) Pub Date : 2024-03-08 Alexander C. Razavi, Paolo Raggi, Seamus P. Whelton
-
Low-level ambient ozone exposure associated with neutrophil extracellular traps and pro-atherothrombotic biomarkers in healthy adults Atherosclerosis (IF 5.3) Pub Date : 2024-03-07 Hongbing Xu, Xinghou He, Bin Zhang, Mengyao Li, Yutong Zhu, Tong Wang, Shengcong Liu, Mushui Shu, Ding Ding, Yu Wang, Qian Zhao, Jianping Li, Xiaoming Song, Wei Huang
Uncertainty of the causality determinations for ambient ozone (O) on cardiovascular events is heightened by limited understanding of the mechanisms involved in humans. We aimed to examine the pro-atherothrombotic impacts of O exposure and to explore the potential mediating roles of dysfunctional neutrophils, focusing on neutrophil extracellular traps (NETs). A longitudinal panel study of 152 healthy
-
Effects of alirocumab on endothelial function and coronary atherosclerosis in myocardial infarction: A PACMAN-AMI randomized clinical trial substudy Atherosclerosis (IF 5.3) Pub Date : 2024-03-06 Emrush Rexhaj, Sarah Bär, Rodrigo Soria, Yasushi Ueki, Jonas D. Häner, Tatsuhiko Otsuka, Raminta Kavaliauskaite, George CM. Siontis, Stefan Stortecky, Hiroki Shibutani, David Spirk, Thomas Engstrøm, Irene Lang, Laura Morf, Maria Ambühl, Stephan Windecker, Sylvain Losdat, Konstantinos C. Koskinas, Lorenz Räber, on behalf of the PACMAN-AMI Investigators
The effects of protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on endothelial function as assessed by flow-mediated dilation (FMD) in patients with acute myocardial infarction (AMI) are unknown. Therefore, we aimed to investigate the effects of the PCSK9 inhibitor alirocumab added to high-intensity statin on FMD, and its association with coronary atherosclerosis in non-infarct related
-
Closing the sex gap in cardiovascular mortality by achieving both horizontal and vertical equity Atherosclerosis (IF 5.3) Pub Date : 2024-03-06 Raffaele Bugiardini, Martha Gulati
Addressing sex differences and disparities in coronary heart disease (CHD) involves achieving both horizontal and vertical equity in healthcare. Horizontal equity in the context of CHD means that both men and women with comparable health statuses should have equal access to diagnosis, treatment, and management of CHD. To achieve this, it is crucial to promote awareness among the general public about
-
Matrix gla protein and the long-term incidence and progression of coronary artery and aortic calcification in the multi-ethnic study of atherosclerosis Atherosclerosis (IF 5.3) Pub Date : 2024-03-05 Ashley A. Berlot, Xueyan Fu, M Kyla Shea, Russell Tracy, Matthew Budoff, Ryung S. Kim, Mahim Naveed, Sarah L. Booth, Jorge R. Kizer, Anna E. Bortnick
Matrix Gla protein (MGP) is an inhibitor of calcification that requires carboxylation by vitamin K for activity. The inactive form of MGP, dephosphorylated-uncarboxylated matrix Gla protein (dp-ucMGP), has been associated with increased calcification. However, it is not known whether there is a longitudinal relationship between dephosphorylated-uncarboxylated matrix Gla protein levels and coronary
-
Rosuvastatin effect on atherosclerotic plaque metabolism: A subclinical atherosclerosis imaging study with 18F–NaF PET-CT Atherosclerosis (IF 5.3) Pub Date : 2024-02-29 Manuel Oliveira-Santos, João Borges-Rosa, Rodolfo Silva, Luís Paixão, Cláudio Espírito Santo, Antero Abrunhosa, Miguel Castelo-Branco, Piotr J. Slomka, Lino Gonçalves, Maria João Ferreira
Atherosclerotic plaque fluorine-18 sodium fluoride (F–NaF) uptake on positron emission tomography with computed tomography (PET-CT) identifies active microcalcification and has been shown to correlate with clinical instability in patients with cardiovascular (CV) disease. Statin therapy promotes coronary macrocalcification over time. Our aim was to investigate rosuvastatin effect on atheroma F–NaF
-
Identification of circular RNA hsa_circ_0034621 as a novel biomarker for carotid atherosclerosis and the potential function as a regulator of NLRP3 inflammasome Atherosclerosis (IF 5.3) Pub Date : 2024-02-29 Yu-Xiang Yan, Ya-Ke Lu, Yu-Hong Liu, Jie Zhang, Shuo Wang, Jing Dong, Huan-Bo Xiao
NLRP3 inflammasome plays a key role in vascular inflammation and atherosclerosis. Circular RNAs (circRNAs) are involved in disease development by regulating gene expression, and have emerged as promising novel disease biomarkers. This study aimed to identify the NLRP3 inflammasome-associated circRNA biomarkers of carotid atherosclerosis. Based on the differential expression profiles of circRNAs in
-
Predicting the response to acetylcholine in ischemia or infarction with non-obstructive coronary arteries: The ABCD score Atherosclerosis (IF 5.3) Pub Date : 2024-02-28 Riccardo Rinaldi, Michele Colucci, Ilaria Torre, Davide Ausiello, Alice Bonanni, Mattia Basile, Carmine Salzillo, Tommaso Sanna, Giovanna Liuzzo, Antonio M. Leone, Francesco Burzotta, Carlo Trani, Gaetano A. Lanza, Giampaolo Niccoli, Filippo Crea, Rocco A. Montone
Acetylcholine (ACh) provocation testing can detect vasomotor disorders in patients with ischemia and non-obstructed coronary arteries (INOCA) or myocardial infarction and non-obstructed coronary arteries (MINOCA). We aimed to derive and validate a simple risk score to predict a positive ACh test response. We prospectively enrolled consecutive INOCA and MINOCA patients undergoing ACh provocation testing
-
Comparative effects of glucose-lowering agents on endothelial function and arterial stiffness in patients with type 2 diabetes: A network meta-analysis Atherosclerosis (IF 5.3) Pub Date : 2024-02-28 Hayeon Kim, Cheol Ung Choi, Kiyon Rhew, Jiwon Park, Yejee Lim, Myeong Gyu Kim, Kyungim Kim
Despite accumulating evidence on the potential of glucose-lowering agents (GLAs) to prevent cardiovascular events, the comparative effects of GLAs on vascular function remain unclear. This study utilized validated indicators such as flow-mediated dilation (FMD; positive value favors) and pulse wave velocity (PWV; negative value favors) to uncover the comparative effects of GLAs on vascular function
-
Drug target mendelian randomization supports apolipoprotein C3-lowering for lipoprotein-lipid levels reductions and cardiovascular diseases prevention Atherosclerosis (IF 5.3) Pub Date : 2024-02-28 Eloi Gagnon, Benoit J. Arsenault
Inhibitors of apolipoprotein C-III (apoC3) are currently approved for the reduction of triglyceride levels in patients with Familial Chylomicronemia Syndrome. We used drug target Mendelian randomization (MR) to assess the effect of genetically predicted decrease in apoC3 blood protein levels on cardiometabolic traits and diseases. We quantified lifelong reductions in apoC3 blood levels by selecting
-
Tracking of serum lipid levels from childhood to adulthood: Systematic review and meta-analysis Atherosclerosis (IF 5.3) Pub Date : 2024-02-27 Oliver Stanesby, Matthew K. Armstrong, Petr Otahal, James P. Goode, Brooklyn J. Fraser, Kazuaki Negishi, Tetsuhiro Kidokoro, Tania Winzenberg, Markus Juonala, Feitong Wu, Rebecca K. Kelly, Bo Xi, Jorma S.A. Viikari, Olli T. Raitakari, Stephen R. Daniels, Grant R. Tomkinson, Costan G. Magnussen
The utility of lipid screening in pediatric settings for preventing adult atherosclerotic cardiovascular diseases partly depends on the lifelong tracking of lipid levels. This systematic review aimed to quantify the tracking of lipid levels from childhood and adolescence to adulthood. We systematically searched MEDLINE, Embase, Web of Science, and Google Scholar in March 2022. The protocol was registered
-
Acute pancreatitis risk in multifactorial chylomicronemia syndrome depends on the molecular cause of severe hypertriglyceridemia Atherosclerosis (IF 5.3) Pub Date : 2024-02-27 Simon-Pierre Guay, Martine Paquette, Amélie Taschereau, Lysanne Girard, Véronique Desgagné, Luigi Bouchard, Sophie Bernard, Alexis Baass
Multifactorial chylomicronemia syndrome (MCS) is a severe form of hypertriglyceridemia (hyperTG) associated with an increased risk of acute pancreatitis (AP). Severe hyperTG is mainly polygenic in nature, either caused by the presence of heterozygous pathogenic variants (PVs) in TG-related metabolism genes or by accumulation of common variants in hyperTG susceptibility genes. This study aims to determine
-
Antisense oligonucleotide targeting hepatic Serum Amyloid A limits the progression of angiotensin II-induced abdominal aortic aneurysm formation Atherosclerosis (IF 5.3) Pub Date : 2024-02-26 Preetha Shridas, Ailing Ji, Andrea C. Trumbauer, Victoria P. Noffsinger, Luke W. Meredith, Frederick C. de Beer, Adam E. Mullick, Nancy R. Webb, Dennis G. Karounos, Lisa R. Tannock
Obesity increases the risk for abdominal aortic aneurysms (AAA) in humans and enhances angiotensin II (AngII)-induced AAA formation in C57BL/6 mice. We reported that deficiency of Serum Amyloid A (SAA) significantly reduces AngII-induced inflammation and AAA in both hyperlipidemic apoE-deficient and obese C57BL/6 mice. The aim of this study is to investigate whether SAA plays a role in the progression
-
SIRT6 mediated vascular smooth muscle cells senescence participates in the pathogenesis of abdominal aortic aneurysm Atherosclerosis (IF 5.3) Pub Date : 2024-02-24 Le Yang, Xuejun Wu, Shuai Bian, Dongfang Zhao, Sheng Fang, Hai Yuan
In this study, we carried out clinical sample study, in vivo study and in vitro study to evaluate the effect of SIRT6 and SIRT6 mediated vascular smooth muscle senescence on the development of AAA. AAA specimen showed an increased P16, P21 level and a decreased SIRT6 level compared with control aorta. Time curve study of Ang II infusion AAA model showed similar P16, P21 and SIRT6 change at the early
-
Insulin resistance is an important index to assess glucose and insulin metabolism, but not a biological risk factor for high-risk coronary artery plaque composition Atherosclerosis (IF 5.3) Pub Date : 2024-02-19 Venera Berisha-Muharremi, Ljiljana Majnaric-Trtica, Blerim Mujaj
-
Outcomes of management strategies in patients with prior coronary artery bypass grafting presenting with an acute coronary syndrome Atherosclerosis (IF 5.3) Pub Date : 2024-02-16 Pishoy Gouda, Sunjidatul Islam, Douglas C. Dover, Padma Kaul, Kevin R. Bainey, Robert C. Welsh
Patients with prior coronary artery bypass grafting (CABG) presenting with an acute coronary syndrome (ACS) have poor outcomes and the optimal treatment strategy for this population is unknown. Using linked administrative databases, we examined patients with an ACS between 2008 and 2019, identifying patients with prior CABG. Patients were categorized by ACS presentation type and treatment strategy
-
Estimating potential cardiovascular health benefits of improved population level control of LDL cholesterol through a twice-yearly siRNA-based approach: A simulation study of a health-system level intervention Atherosclerosis (IF 5.3) Pub Date : 2024-02-15 Kausik K. Ray, Laura H. Gunn, Lorena Garcia Conde, Frederick J. Raal, R. Scott Wright, Nathalie H. Gosselin, Lawrence A. Leiter, Wolfgang Koenig, Gregory G. Schwartz, Ulf Landmesser, the ORION investigators
Inclisiran, an siRNA therapy, consistently reduces low-density lipoprotein cholesterol (LDL-C) with twice-yearly dosing. Potential cardiovascular benefits of implementing inclisiran at a population level, added to statins, were evaluated through simulation. For each participant in the ORION-10 and ORION-11 trials comparing inclisiran with placebo, baseline 10-year cardiovascular risk was estimated
-
Validation of the familial chylomicronaemia syndrome (FCS) score in an ethnically diverse cohort from UK FCS registry: Implications for diagnosis and differentiation from multifactorial chylomicronaemia syndrome (MCS) Atherosclerosis (IF 5.3) Pub Date : 2024-02-10 Bilal Bashir, See Kwok, Anthony S. Wierzbicki, Alan Jones, Charlotte Dawson, Paul Downie, Fiona Jenkinson, Hannah Delaney, Michael Mansfield, Dev Datta, Yee Teoh, Paul Hamilton, Natalie Forrester, Dawn O'Sullivan, Maryam Ferdousi, Paul N. Durrington, Alaa AbdelRazik, Antonio Gallo, Philippe Moulin, Handrean Soran
Prognosis and management differ between familial chylomicronaemia syndrome (FCS), a rare autosomal recessive disorder, and multifactorial chylomicronaemia syndrome (MCS) or severe mixed hyperlipidaemia. A clinical scoring tool to differentiate these conditions has been devised but not been validated in other populations. The objective of this study was to validate this score in the UK population and
-
Coptisine inhibits neointimal hyperplasia through attenuating Pak1/Pak2 signaling in vascular smooth muscle cells without retardation of re-endothelialization Atherosclerosis (IF 5.3) Pub Date : 2024-02-09 Yuhan Chen, Xueze Jiang, Yuchan Yuan, Yuanyuan Chen, Sisi Wei, Ying Yu, Qing Zhou, Yi Yu, Julie Wang, Hua Liu, Xuesheng Hua, Zhenwei Yang, Zhiyong Chen, Yigang Li, Qunshan Wang, Jie Chen, Yuepeng Wang
Vascular injury-induced endothelium-denudation and profound vascular smooth muscle cells (VSMCs) proliferation and dis-regulated apoptosis lead to post-angioplasty restenosis. Coptisine (CTS), an isoquinoline alkaloid, has multiple beneficial effects on the cardiovascular system. Recent studies identified it selectively inhibits VSMCs proliferation. However, its effects on neointimal hyperplasia,
-
Novel plasma biomarkers of coronary artery calcium incidence or progression: Insights from the prospective multi-ethnic Dallas Heart Study cohort Atherosclerosis (IF 5.3) Pub Date : 2024-02-01 Tzlil Grinberg, Alon Eisen, Yeela Talmor-Barkan, Ran Kornowski, Ashraf Hamdan, Guy Witberg, Colby Ayers, Parag Joshi, Anand Rohatgi, Amit Khera, James A. de Lemos, Ian J. Neeland
-
MTMR7 suppresses the phenotypic switching of vascular smooth muscle cell and vascular intimal hyperplasia after injury via regulating p62/mTORC1-mediated glucose metabolism Atherosclerosis (IF 5.3) Pub Date : 2024-02-01 Xiongshan Sun, Yao Yang, Weiwei Zhao, Mingliang Wang, Yingmei Chen, Jia Wang, Dachun Yang, Yongjian Yang
-
Prioritising genetic findings for drug target identification and validation Atherosclerosis (IF 5.3) Pub Date : 2024-01-26 Nikita Hukerikar, Aroon D. Hingorani, Folkert W. Asselbergs, Chris Finan, Amand F. Schmidt
-
Diagnostic challenge of an APOB variant of uncertain significance resolved by transheterozygosity with a pathological LDLR variant and clinical response to therapy Atherosclerosis (IF 5.3) Pub Date : 2024-01-26 A, m, n, o, n, , S, c, h, l, e, g, e, l
Abstract not available
-
Engineering blood and lymphatic microvascular networks Atherosclerosis (IF 5.3) Pub Date : 2024-01-23 Aldina Crnic, Sabrina Rohringer, Tatiana Tyschuk, Wolfgang Holnthoner
-
Sex differences in coronary atherosclerosis during the pre- and postmenopausal period: The Tampere Sudden Death Study Atherosclerosis (IF 5.3) Pub Date : 2024-01-24 Emma Hakamaa, Sirkka Goebeler, Mika Martiskainen, Anne-Mari Louhelainen, Katja Ahinko, Terho Lehtimäki, Pekka Karhunen
-
Comparison of interleukin-6 and high-sensitivity C-reactive protein for cardiovascular risk assessment: Findings from the MESA study Atherosclerosis (IF 5.3) Pub Date : 2024-01-24 João Pedro Ferreira, Francisco Vasques-Nóvoa, João Sérgio Neves, Faiez Zannad, Adelino Leite-Moreira
-
Elevated plasma apolipoprotein E levels in people living with HIV: Associations with biomarkers and HIV-specific risk factors Atherosclerosis (IF 5.3) Pub Date : 2024-01-21 Anne Marie Reimer Jensen, Ruth Frikke-Schmidt, Marco Gelpi, Andreas D. Knudsen, Thomas Benfield, Børge G. Nordestgaard, Shoaib Afzal, Tor Biering-Sørensen, Susanne Dam Nielsen
-
Metabolic reprogramming of immune cells by mitochondrial division inhibitor-1 to prevent post-vascular injury neointimal hyperplasia Atherosclerosis (IF 5.3) Pub Date : 2024-01-14 Gustavo E. Crespo-Avilan, Sauri Hernandez-Resendiz, Chrishan J. Ramachandra, Victor Ungureanu, Ying-Hsi Lin, Shengjie Lu, Jürgen Bernhagen, Omar El Bounkari, Klaus T. Preissner, Elisa A. Liehn, Derek J. Hausenloy
-
Reply to: “Comments on “Higher exercise capacity, but not omega-3 fatty acid consumption, predicts lower coronary artery calcium scores in women and men with coronary artery disease”” Atherosclerosis (IF 5.3) Pub Date : 2024-01-14 Georges Chedid, Abdulaziz Malik, Ralph Daher, Francine K. Welty
Abstract not available
-
Dietary oily fish intake is inversely associated with moderate-to-severe intracranial artery stenosis in older adults of indigenous Ecuadorian ancestry Atherosclerosis (IF 5.3) Pub Date : 2024-01-12 Oscar H. Del Brutto, Robertino M. Mera, Tatjana Rundek, Victor J. Del Brutto, Farid Khasiyev, Denisse A. Rumbea, Mitchell S.V. Elkind, José Gutierrez
-
Comprehensive biomechanical and anatomical atherosclerotic plaque metrics predict major adverse cardiovascular events: A new tool for clinical decision making Atherosclerosis (IF 5.3) Pub Date : 2024-01-11 Sophie Z. Gu, Mona E. Ahmed, Yuan Huang, Diaa Hakim, Charles Maynard, Nicholas V. Cefalo, Ahmet U. Coskun, Charis Costopoulos, Akiko Maehara, Gregg W. Stone, Peter H. Stone, Martin R. Bennett
-
Air pollution and acute coronary syndrome: The air we breathe Atherosclerosis (IF 5.3) Pub Date : 2024-01-11 Safi U. Khan, Mouaz H. Al-Mallah
Abstract not available
-
Atherothrombotic and thrombolytic biomarkers in incident stroke and atrial fibrillation-related stroke: The Multi-Ethnic Study of Atherosclerosis (MESA) Atherosclerosis (IF 5.3) Pub Date : 2024-01-10 Karita Claudia Freitas Lidani, Patrick James Trainor, Harpreet S. Bhatia, Khurram Nasir, Michael J. Blaha, Michael Y. Tsai, Rebecca F. Gottesman, Wendy S. Post, George Thanassoulis, Sotirios Tsimikas, Susan R. Heckbert, Andrew Paul DeFilippis
-
TRIM65 promotes vascular smooth muscle cell phenotypic transformation by activating PI3K/Akt/mTOR signaling during atherogenesis Atherosclerosis (IF 5.3) Pub Date : 2023-12-30 Zhi-Xiang Zhou, Xiao-Feng Ma, Wen-Hao Xiong, Zhong Ren, Miao Jiang, Nian-Hua Deng, Bo-Bin Zhou, Hui-Ting Liu, Kun Zhou, Heng-Jing Hu, Hui-Fang Tang, He Zheng, Zhi-Sheng Jiang
-
Higher prevalence of coronary microvascular dysfunction in asymptomatic individuals with high levels of lipoprotein(a) with and without heterozygous familial hypercholesterolaemia Atherosclerosis (IF 5.3) Pub Date : 2023-12-30 Tigist Wodaje, Ali Mahdi, Ashwin Venkateshvaran, Henrike Häbel, Robin Zenlander, Benjamin Gaylard, Bo Angelin, John Pernow, Jonas Brinck
-
Novel role of peptidoglycan recognition protein 2 in activating NOD2-NFκB inflammatory axis in coronary artery disease Atherosclerosis (IF 5.3) Pub Date : 2023-12-27 Pratitusti Basu, Apabrita Ayan Das, Khawer N. Siddiqui, Prakas C. Mondal, Arun Bandyopadhyay
-
Increasing lipids with risk of worsening cardiac damage in 1595 adolescents: A 7-year longitudinal and mediation study Atherosclerosis (IF 5.3) Pub Date : 2023-12-27 Andrew O. Agbaje
-
Familial hypercholesterolemia diagnostic challenge – is Artificial Intelligence the key? Atherosclerosis (IF 5.3) Pub Date : 2023-12-27 Maria Margarida Andrade, Tiago Neto Gonçalves, Diogo Cruz
Abstract not available
-
The gut microbe-derived metabolite trimethylamine-N-oxide induces aortic valve fibrosis via PERK/ATF-4 and IRE-1α/XBP-1s signaling in vitro and in vivo Atherosclerosis (IF 5.3) Pub Date : 2023-12-27 Zhenyu Xiong, Jiaying Li, Rihua Huang, Huimin Zhou, Xingfeng Xu, Shaozhao Zhang, Peihan Xie, Miaohong Li, Yue Guo, Xinxue Liao, Xiaodong Zhuang
-
Perinatal exposures and adolescence overweight: The role of shared maternal-offspring pathways Atherosclerosis (IF 5.3) Pub Date : 2023-12-27 Ilona Shapiro, Iaroslav Youssim, Ora Paltiel, Ronit Calderon-Margalit, Orly Manor, Yechiel Friedlander, Hagit Hochner
-
Net adverse clinical events with P2Y12 inhibitor therapy in older patients after percutaneous coronary interventions Atherosclerosis (IF 5.3) Pub Date : 2023-12-27 Edina Cenko, Olivia Manfrini, Raffaele Bugiardini
Abstract not available
-
Elevated lipoprotein(a) increases risk of subsequent major adverse cardiovascular events (MACE) and coronary revascularisation in incident ASCVD patients: A cohort study from the UK Biobank Atherosclerosis (IF 5.3) Pub Date : 2023-12-27 Paul Welsh, Anas Al Zabiby, Hannah Byrne, Harriet R. Benbow, Taha Itani, Gabriella Farries, Madlaina Costa-Scharplatz, Philippe Ferber, Lorraine Martin, Rosemary Brown, Ana Filipa Fonseca, Naveed Sattar
-
Hypercholesterolemia exacerbates in-stent restenosis in rabbits: Studies of the mitigating effect of stent surface modification with a CD47-derived peptide Atherosclerosis (IF 5.3) Pub Date : 2023-12-24 Ilia Fishbein, Vaishali V. Inamdar, Ivan S. Alferiev, George Bratinov, Menekhem M. Zviman, Anna Yekhilevsky, Chandrasekaran Nagaswami, Kristin L. Gardiner, Robert J. Levy, Stanley J. Stachelek
-
Dietary fat quality, plasma atherogenic lipoproteins, and atherosclerotic cardiovascular disease: An overview of the rationale for dietary recommendations for fat intake Atherosclerosis (IF 5.3) Pub Date : 2023-12-23 Jacob J. Christensen, Erik Kristoffer Arnesen, Amanda Rundblad, Vibeke H. Telle-Hansen, Ingunn Narverud, Rune Blomhoff, Martin P. Bogsrud, Kjetil Retterstøl, Stine M. Ulven, Kirsten B. Holven
-
Flagellar hook protein FlgE promotes macrophage activation and atherosclerosis by targeting ATP5B Atherosclerosis (IF 5.3) Pub Date : 2023-12-23 Yuanyuan Li, Min Zhang, Yanmeng Li, Ying shen, Xiaoping Wang, Xiaolu Li, Yiqiang Wang, Tao Yu, Jie Lv, Yan Qin
-
Inhibition of chymase-dependent production of IL-1β by smooth muscle cells in the fibrous caps of human atherosclerotic plaques: A reasonable approach to prevent cap rupture? Atherosclerosis (IF 5.3) Pub Date : 2023-12-17 P, e, t, r, i, , T, ., , K, o, v, a, n, e, n
Abstract not available
-
Macrophage-targeted ultrasound nanobubbles for highly efficient sonodynamic therapy of atherosclerotic plaques by modulating M1-to-M2 polarization Atherosclerosis (IF 5.3) Pub Date : 2023-12-13 Yueying Chen, Hao Wang, Juhong Pan, Yuxin Guo, Yugang Hu, Xin Huang, Yanxiang Zhou, Qing Deng, Qing Zhou
-
Net clinical benefit of clopidogrel versus ticagrelor in elderly patients carrying CYP2C19 loss-of-function variants with acute coronary syndrome after percutaneous coronary intervention Atherosclerosis (IF 5.3) Pub Date : 2023-12-13 Dali Zhang, Pengxiao Li, Miaohan Qiu, Zhenyang Liang, Jiaqi He, Yi Li, Yaling Han
-
Statin therapy and outcome in Takotsubo syndrome patients: Results from the multicenter international GEIST registry Atherosclerosis (IF 5.3) Pub Date : 2023-12-13 Giuseppina Novo, Luca Arcari, Thomas Stiermaier, Chiara Alaimo, Ibrahim El-Battrawy, Luca Cacciotti, Federico Guerra, Beatrice Musumeci, Enrica Mariano, Giuseppe Parisi, Roberta Montisci, Ravi Vazirani, Alberto Perez Castellanos, Aitor Uribarri, Miguel Corbi-Pascual, Jorge Salamanca, Ibrahim Akin, Holger Thiele, Natale Daniele Brunetti, Ingo Eitel, Francesco Santoro
-
Association between long-term exposure to ambient air pollution and lesion ischemia in patients with atherosclerosis Atherosclerosis (IF 5.3) Pub Date : 2023-12-12 Muwu Xu, Zhihui Hou, Nadia Koyratty, Conghong Huang, Lina Mu, Kexin Zhu, Guan Yu, Michael J. LaMonte, Matthew J. Budoff, Joel D. Kaufman, Meng Wang, Bin Lu
-
Differential effect of atorvastatin and pravastatin on thoracic spine attenuation: A sub-analysis of a randomized clinical trial Atherosclerosis (IF 5.3) Pub Date : 2023-12-12 Paolo Raggi, Farzin M. Takyar, Varuna Gadiyaram, Chao Zhang, Arthur E. Stillman, Amir H. Davarpanah
-
Pro-osteogenic role of interleukin-22 in calcific aortic valve disease Atherosclerosis (IF 5.3) Pub Date : 2023-12-11 huifang Deng, Huadong Li, Zongtao Liu, Na Shen, Nianguo Dong, Cheng Deng, Fayuan Liu
-
Coronary artery calcium screening: He who buys what he does not need steals from himself Atherosclerosis (IF 5.3) Pub Date : 2023-12-10 Vishnu Kadiyala, Vishal Khetpal, Edward A. Hulten
Abstract not available
-
Comments on “Higher exercise capacity, but not omega-3 fatty acid consumption, predicts lower coronary artery calcium scores in women and men with coronary artery disease” Atherosclerosis (IF 5.3) Pub Date : 2023-12-10 Naeimehossadat Asmarian, Hadi Raeisi Shahraki
Abstract not available
-
Plasma levels of PRO-C3, a type III collagen synthesis marker, are associated with arterial stiffness and increased risk of cardiovascular death Atherosclerosis (IF 5.3) Pub Date : 2023-12-10 Federica Genovese, Isabel Gonçalves, Signe Holm Nielsen, Morten A. Karsdal, Andreas Edsfeldt, Jan Nilsson, Angela C. Shore, Andrea Natali, Faisel Khan, Annelie Shami
-
Monocyte transcriptomic profile following EPA and DHA supplementation in men and women with low-grade chronic inflammation Atherosclerosis (IF 5.3) Pub Date : 2023-12-03 Jisun So, Dayong Wu, Albert K. Tai, Alice H. Lichtenstein, Nirupa R. Matthan, Stefania Lamon-Fava